Business
Notice of Interim Results & Investor Presentation
Notice of Interim Results & Investor Presentation.
About this update from Ixico Plc
[{"type":"text","content":"\n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nNotice of 2025 Interim results and Investor Presentation\n \n \n06 May 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, confirms it will issue unaudited interim results for the six months ended 31 March 2025 on Tuesday 20 May 2025.\n \nBram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to the Interim Results and the Company's progress and ongoing strategy via:\n \nThe Investor Meet Company platform on 20 May 2025 at 16:30 BST.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 19 May 2025, 09:00 BST, or at any time during the live presentation.\n \nInvestors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:\n \nhttps://www.investormeetcompany.com/ixico-plc/register-investor\n \nInvestors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.\n \nA recording of the results presentation will be made available on the Group's website here: https://ixico.com/investors/company-information/investor-videos/\n \n \nFor further information please contact:\n \n\n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7499\n\n\n\n\nBram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer\n\n\n\n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser and Sole Broker)\n\n\n+44 (0) 20 7220 0500\n\n\n\n\n Giles Balleny / Dan Hodkinson (Corporate Finance)\nNigel Birks (Healthcare Specialist Sales)\nHarriet Ward (Corporate Broking)\nMichael F Johnson (Sales)\n\n\n\n\n\n\n\n \n \nAbout IXICO www.IXICO.com\nIXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track ...